Patents by Inventor Bo-Eric PERSSON

Bo-Eric PERSSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240316142
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Application
    Filed: May 31, 2024
    Publication date: September 26, 2024
    Applicant: Ferring B.V.
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A. van der Meulen, Jens-Kristian Slott Jensen
  • Publication number: 20220323538
    Abstract: The invention provides methods and dosing regimens for treating metastatic stage prostate cancer in a subject using degarelix, as well as related methods of using degarelix in a subject identified as having metastatic stage prostate cancer, and methods of using degarelix to prevent or delay the progression of locally advanced prostate cancer.
    Type: Application
    Filed: May 31, 2022
    Publication date: October 13, 2022
    Applicant: FERRING INTERNATIONAL CENTER S.A.
    Inventor: Bo-Eric PERSSON
  • Publication number: 20220218783
    Abstract: The invention provides methods and dosing regimens for treating metastatic stage prostate cancer in a subject using degarelix, as well as related methods of using degarelix in a subject identified as having metastatic stage prostate cancer, and methods of using degarelix to prevent or delay the progression of locally advanced prostate cancer.
    Type: Application
    Filed: March 31, 2022
    Publication date: July 14, 2022
    Applicant: FERRING INTERNATIONAL CENTER S.A.
    Inventor: Bo-Eric PERSSON
  • Publication number: 20220218782
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Application
    Filed: March 31, 2022
    Publication date: July 14, 2022
    Applicant: Ferring B.V.
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A. van der Meulen, Jens-Kristian Slott Jensen
  • Publication number: 20220031801
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Application
    Filed: March 12, 2021
    Publication date: February 3, 2022
    Applicant: Ferring B.V.
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A. van der Meulen, Jens-Kristian Slott Jensen
  • Patent number: 10973870
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: April 13, 2021
    Assignee: Ferring B.V.
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A. van der Meulen, Jens-Kristian Slott Jensen
  • Patent number: 10729739
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: August 4, 2020
    Assignee: Ferring B.V.
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A van der Meulen, Jens-Kristian Slott Jensen
  • Publication number: 20200237854
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Application
    Filed: April 17, 2020
    Publication date: July 30, 2020
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A. van der Meulen, Jens-Kristian Slott Jensen
  • Publication number: 20190167755
    Abstract: The invention provides methods and dosing regimens for treating metastatic stage prostate cancer in a subject using degarelix, as well as related methods of using degarelix in a subject identified as having metastatic stage prostate cancer, and methods of using degarelix to prevent or delay the progression of locally advanced prostate cancer.
    Type: Application
    Filed: December 18, 2017
    Publication date: June 6, 2019
    Inventor: Bo-Eric PERSSON
  • Patent number: 9877999
    Abstract: The invention provides methods and dosing regimens for eating metastatic stage prostate cancer in a subject using degarelix, as well as related methods of using degarelix in a subject identified as having metastatic stage prostate cancer, and methods of using degarelix to prevent or delay the progression of locally advanced prostate cancer.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: January 30, 2018
    Assignee: Ferring International Center SA
    Inventor: Bo-Eric Persson
  • Publication number: 20170290879
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Application
    Filed: January 13, 2017
    Publication date: October 12, 2017
    Applicant: Ferring B.V.
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A. van der Meulen, Jens-Kristian Slott Jensen
  • Patent number: 9579359
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: February 28, 2017
    Assignee: FERRING B.V.
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A van der Meulen, Jens-Kristian Slott Jensen
  • Publication number: 20140349935
    Abstract: The invention provides methods and dosing regimens for eating metastatic stage prostate cancer in a subject using degarelix, as well as related methods of using degarelix in a subject identified as having metastatic stage prostate cancer, and methods of using degarelix to prevent or delay the progression of locally advanced prostate cancer.
    Type: Application
    Filed: August 8, 2014
    Publication date: November 27, 2014
    Inventor: Bo-Eric PERSSON
  • Patent number: 8841081
    Abstract: The invention provides methods and dosing regimens for treating metastatic stage prostate cancer in a subject using degarelix, as well as related methods of using degarelix in a subject identified as having metastatic stage prostate cancer, and methods of using degarelix to prevent or delay the progression of locally advanced prostate cancer.
    Type: Grant
    Filed: February 10, 2009
    Date of Patent: September 23, 2014
    Assignee: Ferring International SA
    Inventor: Bo-Eric Persson
  • Publication number: 20140113870
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Application
    Filed: December 24, 2013
    Publication date: April 24, 2014
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A. van der Meulen, Jens-Kristian Slott Jensen
  • Publication number: 20090203623
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Application
    Filed: February 10, 2009
    Publication date: August 13, 2009
    Inventors: Tine Kold OLESEN, Bo-Eric PERSSON, Per CANTOR, Egbert A. van der MEULEN, Jens-Kristian Slott JENSEN
  • Publication number: 20090203622
    Abstract: The invention provides methods and dosing regimens for treating metastatic stage prostate cancer in a subject using degarelix, as well as related methods of using degarelix in a subject identified as having metastatic stage prostate cancer, and methods of using degarelix to prevent or delay the progression of locally advanced prostate cancer.
    Type: Application
    Filed: February 10, 2009
    Publication date: August 13, 2009
    Inventor: Bo-Eric PERSSON
  • Publication number: 20080161404
    Abstract: The present invention relates to a method of treating a metastatic prostate cancer patient by administering to said patient an effective amount of a bicalutamide (4?-cyano-??,??,??-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide) containing formulation capable of delivering at least a mean steady state plasma level of (R)-bicalutamide enantiomer of 40 ?g/ml; and to bicalutamide containing products and formulations capable of delivering the at least mean steady state plasma level of (R)-bicalutamide enantiomer of 40 ?g/ml to a patient in need thereof.
    Type: Application
    Filed: February 21, 2006
    Publication date: July 3, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Kevin Joseph Carroll, Thomas Meredydd Morris, Ian Derek Cockshott, Bo-Eric Persson, Paul Alfred Dickinson
  • Publication number: 20050288230
    Abstract: The present invention relates to a method of enhancing bone mineral density (BMD) in a patient in need thereof by administration of an effective amount of a non-steroidal anti-androgen compound, preferably bicalutamide. Further aspects of the invention include methods of treating prostate cancer in patients at increased risk of bone fracture and the use of anti-androgen compounds, in particular bicalutamide, in the manufacture of a pharmaceutical product for such purposes.
    Type: Application
    Filed: May 13, 2003
    Publication date: December 29, 2005
    Applicant: AstraZeneca AB
    Inventor: Bo-Eric Persson